Robert Andtbacka Discusses T-VEC Trials

April 20, 2016
Robert Andtbacka, MD

Robert Andtbacka, MD, associate professor, Division of Surgical Oncology Department of Surgery, University of Utah School of Medicine, discusses past, present, and future trials for T-VEC.

Robert Andtbacka, MD, associate professor, Division of Surgical Oncology Department of Surgery, University of Utah School of Medicine, discusses past, present, and future trials investigating T-VEC in melanoma.

T-VEC was already approved as a monotherapy, but is currently in ongoing studies to be used as a combination therapy. A phase I study showed that the therapy did not increase toxicity when combined with ipilimumab, and response rate when combining the drugs was high. Another study combined pembrolizumab with T-VEC and also showed no added toxicity and a 56% response rate.

An upcoming phase III study will compare the results of pembrolizumab plus T-VEC with pembrolizumab plus an injectable suspension.